Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the therapeutic benefit and allow studying new approaches for resistant patients.

Methods

We analyzed the TCGA cohort of HNSCC patients in relation to their activation of 26 immune gene expression signatures, as well as their cell type composition, in order to define signaling pathways associated with resistance to ICIs. Results were validated on two cohorts of 102 HNSCC patients and 139 HNSCC patients under treatment with PD-L1 inhibitors, respectively, and a cohort of 108 HNSCC HPV negative patients and by in vitro experiments in HNSCC cell lines.

Results</

SUBMITTER: Sacconi A 

PROVIDER: S-EPMC10687972 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature